Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial

BACKGROUND: Due to their immunomodulatory properties, mesenchymal stem cells (MSCs) have been proposed to have therapeutic potential to improve clinical outcomes in COVID-19. However, the safety and efficacy profile of MSC infusion therapy in patients with non-severe COVID-19 infection has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Karyana, Muhammad, Djaharuddin, Irawaty, Rif’ati, Lutfah, Arif, Mansyur, Choi, Mi Kyung, Angginy, Nova, Yoon, Aeri, Han, Jumi, Josh, Fonny, Arlinda, Dona, Narulita, Asvin, Muchtar, Faisal, Bakri, Rizki Auliah, Irmansyah, s
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972711/
https://www.ncbi.nlm.nih.gov/pubmed/35365239
http://dx.doi.org/10.1186/s13287-022-02812-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972711/
https://www.ncbi.nlm.nih.gov/pubmed/35365239
http://dx.doi.org/10.1186/s13287-022-02812-4

Ejemplares similares